Main Article Content

Abstract

Colchicine is a known anti-inflammatory and antiproliferative drug obtained from plant known as Colchicum autumnale.  In the past it has been used as an antiinflammatory drug in the gout and mediterranean fever and in several off label conditions. Despite concerns about its gastro-intestinal tolerability, drug interactions and narrow therapeutic window, colchicine has shown promise in many cardiovascular diseases including chronic pericarditis and ischaemic heart disease.  Present review has been done with an objective to explore therapeutic and pleotropic anti-inflammatory effects of colchicine in various inflammatory clinical conditions including Covid-19 (SARS-CoV-2).  Literature search has been carried out by all researchers using databases PubMed/MEDLINE, Google Scholar, EMBASE, SCOPUS and Cochrane (central) review. In the era of Covid-19, researchers across the globe are repurposing and exploring the role of colchicine in Covid-19 induced cytokine storm and inflammation.  Using formulations of colchicine through targeted drug delivery approach may help in greater safety and acceptability of colchicine for various inflammatory conditions.

Keywords

Colchicine anti-inflammatory anti-proliferative Covid-19

Article Details

How to Cite
Seema Manak, & Deep Inder. (2022). Revisiting anti-inflammatory potential of colchicine and repurposing use of colchicine in Covid-19: A comprehensive review. International Journal of Research in Pharmacology & Pharmacotherapeutics, 11(2), 97-102. Retrieved from https://ijrpp.com/ijrpp/article/view/430

References

  1. 1. Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou AR, Zacharoulis A, Kolokathis F, Kekeris V, Giannopoulos G. Colchicine pharmacokinetics and mechanism of action. Curr Pharm Des. 2018;24(6):659-63. doi: 10.2174/1381612824666180123110042, PMID 29359661.
  2. 2. Kesselheim AS, Solomon DH. Incentives for drug development – the curious case of colchicine. N Engl J Med. 2010;362(22):2045-7. doi: 10.1056/NEJMp1003126, PMID 20393164.
  3. 3. Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K, Cleman MW, Stefanadis C. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817-25. doi: 10.1016/j.jacc.2013.08.726, PMID 24036026.
  4. 4. Reyes AZ, Hu KA, Teperman J, Wampler Muskardin TL, Tardif JC, Shah B, Pillinger MH. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2021;80(5):550-7. doi: 10.1136/annrheumdis-2020-219174, PMID 33293273.
  5. 5. Leung YY, Yao Hui LL, Kraus VB. Colchicine—update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-50. doi: 10.1016/j.semarthrit.2015.06.013, PMID 26228647.
  6. 6. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060-8. doi: 10.1002/art.27327, PMID 20131255.
  7. 7. Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C, Kingma DW, Horwitz ME, Mansfield E, Holland SM, O’Shea JJ, Rosenberg HF, Malech HL, Kastner DL. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 2000;95(10):3223-31, PMID 10807793.
  8. 8. Gürkan A, Oğuz MM, Boduroğlu Cengiz E, Şenel S. Dermatologic manifestations of colchicine intoxication. Pediatr Emerg Care. 2018 Jul;34(7):e131-3. doi: 10.1097/PEC.0000000000001530, PMID 29912088.
  9. 9. Sadiq NM, Robinson KJ, Terrell JM. Colchicine; Jun 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK431102/.
  10. 10. Schwier NC, Cornelio CK, Boylan PM. A systematic review of the drug–drug interaction between statins and colchicine: patient characteristics, etiologies, and clinical management strategies. Pharmacotherapy. Feb 2022. doi: 10.1002/phar.2674, PMID 35175631.
  11. 11. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999;340(2):115-26. doi: 10.1056/NEJM199901143400207, PMID 9887164.
  12. 12. Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, Hasan AA, Amar S. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol. 2018;72(17):2071-81. doi: 10.1016/j.jacc.2018.08.1043, PMID 30336831.
  13. 13. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31. doi: 10.1056/NEJMoa1707914, PMID 28845751.
  14. 14. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-30. doi: 10.1056/NEJMoa1709118, PMID 28844192.
  15. 15. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-47. doi: 10.1056/NEJMoa2021372, PMID 32865380.
  16. 16. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-505. doi: 10.1056/NEJMoa1912388, PMID 31733140.
  17. 17. Crittenden DB, Lehmann RA, Schneck L, Keenan RT, Shah B, Greenberg JD, Cronstein BN, Sedlis SP, Pillinger MH. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol. 2012;39(7):1458-64. doi: 10.3899/jrheum.111533, PMID 22660810.
  18. 18. Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020;142(20):1890-900. doi: 10.1161/CIRCULATIONAHA.120.050771, PMID 32862667.
  19. 19. Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J. 2021;42(28):2745-60. doi: 10.1093/eurheartj/ehab221, PMID 33961006.
  20. 20. Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016;1(1):CD011047. doi: 10.1002/14651858.CD011047.pub2, PMID 26816301.
  21. 21. Shah B, Allen N, Harchandani B, Pillinger M, Katz S, Sedlis SP, Echagarruga C, Samuels SK, Morina P, Singh P, Karotkin L, Berger JS. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects. Inflammation. 2016;39(1):182-9. doi: 10.1007/s10753-015-0237-7, PMID 26318864.
  22. 22. Mewton N, Roubille F, Bresson D, Prieur C, et al. Effect of colchicine on myocardial injury in acute myocardial infarction. Circulation. 2021 Sep 14;144(11):859-69. doi: 10.1161/CIRCULATIONAHA.121.056177, PMID 34420373.
  23. 23. Lin ZY, Wu CC, Chuang YH, Chuang WL. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci. 2013;93(8):323-8. doi: 10.1016/j.lfs.2013.07.002, PMID 23871804.
  24. 24. Larocque K, Ovadje P, Djurdjevic S, Mehdi M, Green J, Pandey S. Novel analogue of colchicine induces selective pro-death autophagy and necrosis in human cancer cells. PLOS ONE. 2014;9(1):e87064. doi: 10.1371/journal.pone.0087064, PMID 24466327.
  25. 25. Lattuca B, Leclercq F, Macia JC, Gervasoni R, Cung TT, Pasquié JC. Colchicine: A promising drug in clinical translation, A minireview focused on cardiovascular diseases. Cardiol Ther. 2015;2(3):1-4.
  26. 26. Kumar A, Sharma PR, Mondhe DM. Potential anticancer role of colchicine-based derivatives: an overview. Anti Cancer Drugs. 2017;28(3):250-62. doi: 10.1097/CAD.0000000000000464, PMID 28030380.
  27. 27. Dastoli S, Nisticò SP, Morrone P, Patruno C, Leo A, Citraro R, Gallelli L, Russo E, De Sarro G, Bennardo L. Colchicine in managing skin conditions: A systematic review. Pharmaceutics. 2022;14(2):294. doi: 10.3390/pharmaceutics14020294, PMID 35214027.
  28. 28. Cocchi E, Chiale F, Gianoglio B, Deorsola L, Pace Napoleone C, Fagioli F, Peruzzi L. Colchicine: an impressive effect on posttransplant capillary leak syndrome and renal failure. Pediatrics. 2019;143(5):e20182820. doi: 10.1542/peds.2018-2820, PMID 31000685.
  29. 29. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. 2020JAMA. JAMA. 2020;323(13):1239-42. doi: 10.1001/jama.2020.2648, PMID 32091533.
  30. 30. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46-7. doi: 10.1016/S2213-2600(20)30216-2, PMID 32353251.
  31. 31. Pathophysiology transmission, diagnosis, and treatment of coronavirus Disease 2019 (COVID-19): a review | critical care medicine | JAMA | JAMA network [internet]. [cited Jan 30 2021].
  32. 32. Drosos AA, Pelechas E, Drossou V, Voulgari PV. Colchicine against SARS-CoV-2 infection: what is the evidence? Rheumatol Ther. 2022 Feb 2;9(2):379-89. doi: 10.1007/s40744-022-00425-0, PMID 35107804.
  33. 33. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, Dolianitis K, Randou E, Syrigos K, Kotanidou A, Koulouris NG, et al, GRECCO-19 investigators. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open. 2020;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136, PMID 32579195.
  34. 34. Manenti L, Maggiore U, Fiaccadori E, Meschi T, Antoni AD, Nouvenne A, et al. Reduced mortality in COVID-19 patients treated with colchicine: results from a retrospective, observational study. 2021PLoS one 16(3): e0248276.
  35. 35. Della-Torre E, Della-Torre F, Kusanovic M, Scotti R, Ramirez GA, Dagna L, Tresoldi M. Treating COVID-19 with colchicine in community healthcare setting. Clin Immunol. 2020;217:108490. doi: 10.1016/j.clim.2020.108490, PMID 32492478.
  36. 36. Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarraga A, Parra-Medina R. Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatol Clin. 2021;17(7):371-5. doi: 10.1016/j.reumae.2020.05.008, PMID 34301378. Online ahead of print. pmid:32426001.
  37. 37. Tardif JC, Bouabdallaoui N, L’Allier PLL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 2021;9(8):924-32. doi: 10.1016/S2213-2600(21)00222-8, PMID 34051877.
  38. 38. Horby PW, Campbell M, et al. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021.